These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 31649976)

  • 21. Double-blind, placebo-controlled study of oral calcitriol for the treatment of localized and systemic scleroderma.
    Hulshof MM; Bouwes Bavinck JN; Bergman W; Masclee AA; Heickendorff L; Breedveld FC; Dijkmans BA
    J Am Acad Dermatol; 2000 Dec; 43(6):1017-23. PubMed ID: 11100017
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Incapacitating pansclerotic morphea in childhood].
    Ferrandiz C; Henkes J; González J; Peyri J
    Med Cutan Ibero Lat Am; 1981; 9(5):377-82. PubMed ID: 7038353
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Morphea in Middle Anatolia, Turkey: a 5-year single-center experience.
    Bulur I; Erdoğan HK; Karapınar T; Saracoglu ZN
    Postepy Dermatol Alergol; 2017 Aug; 34(4):334-338. PubMed ID: 28951708
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Challenges in the diagnosis and treatment of disabling pansclerotic morphea of childhood: case-based review.
    Soh HJ; Samuel C; Heaton V; Renton WD; Cox A; Munro J
    Rheumatol Int; 2019 May; 39(5):933-941. PubMed ID: 30838436
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Palindromic morphea: multiple recurrence of morphea lesions in a case of systemic sclerosis.
    Mizutani H; Tanaka H; Okada H; Mizutani T; Shimizu M
    J Dermatol; 1992 May; 19(5):298-301. PubMed ID: 1644954
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Severe course of a mutilating pansclerotic circumscribed scleroderma in childhood. Clinical aspects and therapy].
    Stücker M; Schreiber D; Gruss C; Freitag M; von Kobyletzki G; Kerscher M; Altmeyer P
    Hautarzt; 1999 Feb; 50(2):131-5. PubMed ID: 10097957
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pansclerotic morphea with features of eosinophilic fasciitis: distinct entities or part of a continuum?
    Odhav A; Hoeltzel MF; Canty K
    Pediatr Dermatol; 2014; 31(2):e42-7. PubMed ID: 24383741
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of keloidal morphea after treatment with cyclosporine in a case of recalcitrant generalized morphea.
    Dadkhahfar S; Asadi Kani Z; Araghi F; Moravvej H
    Clin Case Rep; 2020 May; 8(5):837-839. PubMed ID: 32477528
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Morphea and Eosinophilic Fasciitis: An Update.
    Mertens JS; Seyger MMB; Thurlings RM; Radstake TRDJ; de Jong EMGJ
    Am J Clin Dermatol; 2017 Aug; 18(4):491-512. PubMed ID: 28303481
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Diagnostic and therapeutic problems of scleroderma].
    Pogorzelska-Antkowiak A; Antkowiak R
    Wiad Lek; 2006; 59(5-6):392-5. PubMed ID: 17017489
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Classification of morphea (localized scleroderma).
    Peterson LS; Nelson AM; Su WP
    Mayo Clin Proc; 1995 Nov; 70(11):1068-76. PubMed ID: 7475336
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Deep morphea.
    Bielsa I; Ariza A
    Semin Cutan Med Surg; 2007 Jun; 26(2):90-5. PubMed ID: 17544960
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phototherapy: a promising treatment option for skin sclerosis in scleroderma?
    Sunderkötter C; Kuhn A; Hunzelmann N; Beissert S
    Rheumatology (Oxford); 2006 Oct; 45 Suppl 3():iii52-iii54. PubMed ID: 16987838
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Soluble CD4 and CD8 in serum from patients with localized scleroderma.
    Sato S; Fujimoto M; Kikuchi K; Ihn H; Tamaki K; Takehara K
    Arch Dermatol Res; 1996 Jun; 288(7):358-62. PubMed ID: 8818182
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metastatic Squamous Cell Carcinoma in a Patient with Disabling Pansclerotic Morphea of Childhood.
    Ruiz-Matta JM; Flores-Bozo LR; Dominguez-Cherit J
    Pediatr Dermatol; 2017 Jul; 34(4):e164-e167. PubMed ID: 28543434
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adult-onset unilateral disabling pansclerotic morphea.
    Singh A; Singhal K; Choudhary S; Bisati S; Arora M
    Indian J Dermatol; 2014 May; 59(3):316. PubMed ID: 24891683
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Scleroderma: what the general dentist should know.
    Spackman GK
    Gen Dent; 1999; 47(6):576-9. PubMed ID: 10687451
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antinuclear antibodies in children with localized scleroderma.
    Rosenberg AM; Uziel Y; Krafchik BR; Hauta SA; Prokopchuk PA; Silverman ED; Laxer RM
    J Rheumatol; 1995 Dec; 22(12):2337-43. PubMed ID: 8835572
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lower lip squamous cell carcinoma in disabling pansclerotic morphea of childhood.
    Petrov I; Gantcheva M; Miteva L; Vassileva S; Pramatarov K
    Pediatr Dermatol; 2009; 26(1):59-61. PubMed ID: 19250408
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical and laboratory features of systemic sclerosis complicated with localized scleroderma.
    Toki S; Motegi S; Yamada K; Uchiyama A; Kanai S; Yamanaka M; Ishikawa O
    J Dermatol; 2015 Mar; 42(3):283-7. PubMed ID: 25582037
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.